Tumorigenesis and the angiogenic switch (original) (raw)

• Hahn, W. C. et al. Rules for making human tumor cells. N. Engl. J. Med. 347, 1593–603 (2002).
  CAS PubMed Google Scholar
• Duesberg, P. et al. How aneuploidy may cause cancer and genetic instability. Anticancer Res. 19, 4887–4906 (1999).
  CAS PubMed Google Scholar
• Pelengaris, S. et al. c-MYC: more than just a matter of life and death. Nature Rev. Cancer 2, 764–776 (2002).
  CAS Google Scholar
• Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988).
  CAS PubMed Google Scholar
• Hanahan, D. et al. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Folkman, J. in Cancer Medicine (Holland, M.D. et al.) 2546 (BC Decker, Hamilton, Ontario, 2000).
  Google Scholar
• Papetti, M. et al. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C497–C970 (2002).
  Google Scholar
• Hlatky, L. et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl Cancer Inst. 94, 883–893 (2002). This important review discusses several misconceptions in the angiogenesis field. It specifically focuses on microvessel density and the information that can and cannot be gained from it.
  PubMed Google Scholar
• Dor, Y. et al. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. 280, C1367–C1374 (2001).
  CAS PubMed Google Scholar
• Kerbel, R. et al. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002). This is a recent and detailed review about anti-angiogenic therapy.
  CAS Google Scholar
• Hanahan, D. et al. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
  CAS PubMed Google Scholar
• Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389–395 (2000).
  CAS PubMed Google Scholar
• Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).
  CAS PubMed Google Scholar
• Benjamin, L. E. et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159–165 (1999).
  CAS PubMed PubMed Central Google Scholar
• Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002).
  PubMed PubMed Central Google Scholar
• Folberg, R. et al. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 156, 361–381 (2000).
  CAS PubMed PubMed Central Google Scholar
• McDonald, D. M. et al. Vasculogenic mimicry: how convincing, how novel, and how significant? Am. J. Pathol. 156, 383–388 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194–1201 (2001).
  CAS PubMed Google Scholar
• Rafii, S. et al. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 9, 631–641 (2002).
  CAS PubMed Google Scholar
• Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193, 1005–1014 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nature Med. 8, 841–849 (2002).
  CAS PubMed Google Scholar
• Pettersson, A. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99–115 (2000).
  CAS PubMed Google Scholar
• Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999). The is the first report showing that tumours do not always start as avascular lesions, but can also initially grow by co-opting existing blood vessels. The co-opted host vasculature does not immediately undergo angiogenesis to support the tumour — it first regresses before hypoxia-induced neovascularization is initiated.
  CAS PubMed Google Scholar
• Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242–248 (2000).
  CAS PubMed Google Scholar
• Stone, J. et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 15, 4738–4747 (1995).
  CAS PubMed PubMed Central Google Scholar
• Hirschi, K. K. et al. Pericytes in the microvasculature. Cardiovasc. Res. 32, 687 (1996).
  CAS PubMed Google Scholar
• Benjamin, L. E. et al. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591–1598 (1998).
  CAS PubMed Google Scholar
• Benjamin, L. E. et al. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl Acad. Sci. USA 94, 8761–8766 (1997).
  CAS PubMed PubMed Central Google Scholar
• Papapetropoulos, A. et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab. Invest. 79, 213–223 (1999).
  CAS PubMed Google Scholar
• Adini, A. et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res. 62, 2749–2752 (2002).
  CAS PubMed Google Scholar
• Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. Cancer 2, 795–803 (2002).
  CAS Google Scholar
• Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575–583 (2001).
  CAS PubMed Google Scholar
• Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8, S62–S67 (2002).
  CAS PubMed Google Scholar
• Maxwell, P. H. et al. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11, 293–299 (2001).
  CAS PubMed Google Scholar
• Black, W. C. et al. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328, 1237–1243 (1993).
  CAS PubMed Google Scholar
• O'Reilly, M. S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS. 79, 273–294 (1997).
  CAS PubMed Google Scholar
• O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277–285 (1997).
  CAS PubMed Google Scholar
• Joseph, I. B. et al. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 56, 3404–3408 (1996).
  CAS PubMed Google Scholar
• Subbaramaiah, K. et al. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 96–102 (2003).
  CAS PubMed Google Scholar
• Iniguez, M. A. et al. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol. Med. 9, 73–78 (2003).
  CAS PubMed Google Scholar
• Lieberman, R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev. 21, 297–309 (2002).
  CAS PubMed Google Scholar
• Hussain, T. et al. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 191, 125–135 (2003).
  CAS PubMed Google Scholar
• Chen, Y. J. et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol. Oncol. 88, 379–385 (2003).
  CAS PubMed Google Scholar
• Folkman, J. et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58 (1989).
  CAS PubMed Google Scholar
• Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737 (2000).
  CAS PubMed Google Scholar
• Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382–1397 (1999).
  CAS PubMed PubMed Central Google Scholar
• Bergers, G. et al. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42, 995 (1998).
  CAS PubMed Google Scholar
• Elson, D. A. et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 60, 1267–1275 (2000).
  CAS PubMed Google Scholar
• Inoue, M. et al. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1, 193–202 (2002).
  CAS PubMed Google Scholar
• Rodriguez-Manzaneque, J. C. et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 98, 12485–12490 (2001).
  CAS PubMed PubMed Central Google Scholar
• Weidner, N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. Pathol. 184, 119–122 (1998).
  CAS PubMed Google Scholar
• Zabrenetzky, V. et al. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59, 191–195 (1994).
  CAS PubMed Google Scholar
• Weinstat-Saslow, D. L. et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54, 6504–6511 (1994).
  CAS PubMed Google Scholar
• Pelengaris, S. et al. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109, 321–334 (2002).
  CAS PubMed Google Scholar
• Watnick, R. S. et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219–231 (2003). This study strengthens the proposition that the angiogenic switch is a crucial step in tumour progression and that is determined by the ultimate balance in pro- and anti-angiogenic factors.
  CAS PubMed Google Scholar
• Vajkoczy, P. et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J. Clin. Invest. 109, 777–785 (2002).
  CAS PubMed PubMed Central Google Scholar
• Holash, J. et al. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18, 5356–5362 (1999).
  CAS PubMed Google Scholar
• Shweiki, D. et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843–845 (1992).
  CAS PubMed Google Scholar
• Tomlinson, F. H. et al. The significance of atypia and histologic malignancy in pilocytic astrocytoma of the cerebellum: a clinicopathologic and flow cytometric study. J. Child Neurol. 9, 301–310 (1994).
  CAS PubMed Google Scholar
• Brem, S. et al. Tumor angiogenesis: a quantitative method for histologic grading. J. Natl Cancer Inst. 48, 347–356 (1972).
  CAS PubMed Google Scholar
• Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388–1393 (2000).
  CAS PubMed Google Scholar
• Rubenstein, J. L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306–314 (2000).
  CAS PubMed PubMed Central Google Scholar
• Filleur, S. et al. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev. 15, 1373–1382 (2001).
  CAS PubMed PubMed Central Google Scholar
• Douglas, M. L. et al. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. BJU Int. 89, 591–595 (2002).
  CAS PubMed Google Scholar
• Yu, J. L. et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526–1528 (2002).
  CAS PubMed Google Scholar
• Gee, M. S. et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res. 59, 4882–4889 (1999).
  CAS PubMed Google Scholar
• Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349–4354 (2002).
  CAS PubMed PubMed Central Google Scholar
• Wang, J. H. et al. Hypoxia upregulates Bcl-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. Cancer 94, 2745–2755 (2002).
  CAS PubMed Google Scholar
• Zhang, X. S. et al. Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacol. Sin. 22, 731–735 (2001).
  CAS PubMed Google Scholar
• Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604–4613 (1996).
  CAS PubMed PubMed Central Google Scholar
• Stein, I. et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 15, 5363–5368 (1995).
  CAS PubMed PubMed Central Google Scholar
• Laderoute, K. R. et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6, 2941–2950 (2000).
  CAS PubMed Google Scholar
• Royds, J. A. et al. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol. Pathol. 51, 55–61 (1998).
  CAS PubMed PubMed Central Google Scholar
• Kwak, C. et al. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int. 89, 303–309 (2002).
  CAS PubMed Google Scholar
• Mukhopadhyay, D. et al. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161–6165 (1995).
  CAS PubMed Google Scholar
• Zhang, L. et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60, 3655–3661 (2000).
  CAS PubMed Google Scholar
• Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34–44 (2000).
  CAS PubMed PubMed Central Google Scholar
• Agani, F. et al. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res. 57, 4474–4477 (1997).
  CAS PubMed Google Scholar
• Holmgren, L. et al. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 17, 819–824 (1998).
  CAS PubMed Google Scholar
• Gautam, A. et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9, 28–36 (2002).
  CAS PubMed Google Scholar
• Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15–R24 (2000).
  CAS PubMed PubMed Central Google Scholar
• Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878–1886 (2000).
  CAS PubMed Google Scholar
• Bergers, G. et al. Combining anti-angiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. CSH Symp. Quant. Biol. 67, 293–300 (2002).
  CAS Google Scholar
• Bergers, G. et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812 (1999).
  CAS PubMed Google Scholar
• Shigematsu, K. et al. Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF. Eur. J. Vasc. Endovasc. Surg. 14, 290–298 (1997).
  CAS PubMed Google Scholar
• Bergers, G. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature. J. Clin. Invest. 111, 1287–1295 (2003).
  CAS PubMed PubMed Central Google Scholar
• Cline, E. I. et al. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res. 62, 7143–7148 (2002).
  CAS PubMed Google Scholar
• Dancey, J. et al. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev. Drug Discov. 2, 296–313 (2003).
  CAS Google Scholar
• Hu, Y. L. et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl Cancer Inst. 93, 762–768 (2001).
  CAS PubMed Google Scholar
• Volpert, O. V. et al. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat. 36, 119–126 (1995).
  CAS PubMed Google Scholar
• Maeshima, Y. et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276, 15240–15248 (2001).
  CAS PubMed Google Scholar
• Kamphaus, G. D. et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275, 1209–1215 (2000).
  CAS PubMed Google Scholar
• Dameron, K. M. et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582–1584 (1994).
  CAS PubMed Google Scholar
• Lawler, J. et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am. J. Pathol. 159, 1949–1956 (2001).
  CAS PubMed PubMed Central Google Scholar
• Nishimori, H. et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 15, 2145–2150 (1997).
  CAS PubMed Google Scholar
• Bian, J. et al. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol. Cell. Biol. 17, 6330–6338 (1997).
  CAS PubMed PubMed Central Google Scholar
• Brantley, D. M. et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21, 7011–7026 (2002).
  CAS PubMed Google Scholar
• Dohn, M. et al. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 20, 6503–6515 (2001).
  CAS PubMed Google Scholar
• Cheng, N. et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 1, 2–11 (2002).
  CAS PubMed Google Scholar
• Sun, Y. et al. Human metalloproteinase-1 (collagenase-1) is a tumor suppressor protein p53 target gene. Ann. NY Acad. Sci. 878, 638–641 (1999).
  CAS PubMed Google Scholar
• Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052–4057 (2000).
  CAS PubMed PubMed Central Google Scholar
• Subbaramaiah, K. et al. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274, 10911–10915 (1999).
  CAS PubMed Google Scholar
• Pal, S. et al. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61, 6952–6957 (2001).
  CAS PubMed Google Scholar
• Moser, T. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl Acad. Sci. USA 96, 2811–2816 (1999).
  CAS PubMed PubMed Central Google Scholar
• Troyanovsky, B. et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell. Biol. 152, 1247–1254 (2001).
  CAS PubMed PubMed Central Google Scholar
• Yeh, R. J. et al. The antiangiogenic agent TNP470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl Acad. Sci. USA 97, 12782–12787 (2000).
  CAS PubMed PubMed Central Google Scholar
• Sternlicht, M. D. et al. Matrix proteinases as emerging targets in anticancer therapy: status and prospects. ETT 4, 609–633 (2000).
  CAS Google Scholar
• Fong, T. A. et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk–1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99 (1999).
  CAS PubMed Google Scholar
• Laird, A. D. et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60, 4152–4160 (2000).
  CAS PubMed Google Scholar